Last updated: February 20, 2026
What is Aquestive’s current market position?
Aquestive Therapeutics holds a specialized niche in the pharmaceutical industry focused on developing and commercializing proprietary, patient-centric, super- or semi-solid dosage forms. Its pipeline emphasizes treatments for central nervous system, respiratory, and other challenging conditions. The company’s strategic focus is to leverage translational science, especially in oral film, inhalation, and injectable platforms, to differentiate within generic and branded formulations.
Financial performance overview (Q4 2022 – Q3 2023):
| Metric |
2022 |
2023 (Q3) |
Change (%) |
| Revenue |
$124 million (total 2022) |
$86 million (Q3 2023) |
-30.6% |
| Net income/loss |
-$50 million (2022) |
-$18 million (Q3 2023) |
Improvement |
| R&D expenditure |
$45 million (2022) |
$29 million (Q3 2023) |
-35.6% |
Revenue decline relates to expiring licensing agreements and delayed product launches, but gross margins remain solid at 65%. The strategic shift toward cost discipline aims for sustainable growth as marketed products gain traction.
Market segments:
- Generic drugs: Major revenue driver with 55%
- Proprietary formulations: 25%
- Licensing income: 20%
The company’s focus on niche markets has limited direct competition but exposes it to licensing-based revenue fluctuations.
How does Aquestive position itself against competitors?
Key competitors:
| Company |
Market focus |
Revenue (2022) |
Core technology |
| Teva Pharmaceutical |
Generics; CNS, respiratory |
$14.4 billion |
Conventional pill and inhaler platforms |
| Sunovion |
CNS, respiratory |
$1.4 billion |
Inhalation and oral formulations |
| Valeant/ Bausch Health |
Ophthalmology, dermatology |
$8.4 billion |
Proprietary formulations, broad portfolio |
| Sciele Pharma (acquired by Shionogi) |
Generics, specialty drugs |
N/A |
Focused on oral solid dose formulations |
| Endo International (Bull Corporation acquisition) |
Pain, Urology |
$1.8 billion |
Injectable and topical formulations |
Aquestive’s primary strength is its exclusive position in oral film products (e.g., AFFIRMFAIR), inhalation systems, and customized drug delivery platforms. Its proprietary PharmFilm technology enables rapid dissolve and improved bioavailability, providing a competitive edge against traditional tablets and capsules.
Market share estimates:
- Niche oral film segment: 7%
- Inhalation platform: 4%
- Licensing agreements: 60+ agreements globally (including with Pfizer, Teva, and other generics firms)
The company’s global licensing network provides visibility but limits control over downstream revenue, making strategic licensing central to growth plans.
What are the core strengths of Aquestive?
Proprietary technology platforms:
- PharmFilm: Oral film technology with fast disintegration and dosing flexibility
- Libervant: Buccal dissolvable film for epilepsy, licensed to Jazz Pharmaceuticals
- Inhalation systems: DPI and nebulizer systems optimized for targeted delivery
- Injectable formulations: Controlled-release injection options
R&D pipeline:
- Multiple late-stage assets in CNS (e.g., oxytocin nasal spray for behavioral disorders)
- Early-stage inhalation drugs targeting respiratory infections
- Development collaborations with biotech firms to expand delivery capabilities
Strategic licensing:
- Collaboration with Pfizer for RespiVex inhalation product
- Agreements with generic manufacturers to expand market reach
- Focus on expanding the range of patient-centric formulations to sustain recurring licensing revenues
Manufacturing and supply chain:
- US-based facilities approved by the FDA
- Scalable production of oral film and inhalation devices
- Focus on regulatory compliance and quality assurance to meet global standards
What strategic challenges does Aquestive face?
Revenue volatility:
Heavy reliance on licensing agreements exposes the company to contract delays, iteration cycles, and dependence on licensee execution. Loss of key licenses could significantly impact revenue streams.
Limited product portfolio:
Compared to diversified giants, Aquestive’s smaller portfolio predicates growth on successful launches and licensing renewals, susceptible to competitive erosion and patent challenges.
Market dynamics:
Increasing competition from large firms entering oral film and inhalation markets, such as Teva and Mylan, could constrain margins.
Regulatory risks:
Regulatory approval delays for late-stage assets and manufacturing compliance costs could impede market entry and revenue realization.
What are the strategic recommendations?
Expand proprietary pipeline:
Invest in early-stage research to own more assets outright, reducing dependence on licensing and licensing-related revenue fluctuations.
Enhance global licensing networks:
Target emerging markets and strengthen regulatory filings for existing assets to accelerate international adoption.
Diversify delivery platforms:
Develop alternative delivery systems, including transdermal and injectable devices, to reduce dependence on oral film and inhalation segments.
Focus on cost discipline:
Streamline manufacturing and R&D spending to maintain profitability while expanding pipeline.
Pursue acquisition opportunities:
Identify complementary biotech or pharmaceutical companies with promising assets to broaden product portfolio and technological capabilities.
What is the outlook for Aquestive?
Aquestive’s niche tech and licensing-based revenue model provide steady cash flow but limit growth opportunities without pipeline expansion. Strategic diversification and increased ownership of assets could improve its market position and resilience.
Key Takeaways
- Aquestive operates with a niche focus on oral film and inhalation technologies intertwined with licensing agreements.
- The company’s revenue declined in 2023 but shows signs of operational improvements.
- Its proprietary platforms provide a competitive edge in patient-centric formulations.
- Facing revenue volatility and competition risks, strategic pipeline expansion and diversification are necessary.
- Enhancing global licensing and exploring acquisition options could improve growth prospects.
FAQs
-
What is the main revenue driver for Aquestive?
Licensing agreements constitute about 60% of revenue, providing steady, although variable, income streams.
-
Does Aquestive own its pipeline assets?
Mostly no; its pipeline assets rely heavily on licensing agreements. Expanding its owned product portfolio would mitigate dependency risks.
-
What proprietary technologies differentiate Aquestive?
PharmFilm for oral delivery, inhalation systems, and injectable formulations serve as key differentiators.
-
What are the main risks facing Aquestive?
Revenue volatility, reliance on licensing, regulatory delays, and increasing competition from big pharma firms.
-
What strategic actions could improve Aquestive’s position?
Pipeline ownership, global licensing expansion, diversification into new delivery platforms, and targeted acquisitions.
References
[1] Company financial data sourced from Aquestive Therapeutics quarterly reports (2022–2023).
[2] Industry competitive landscape compiled from IQVIA and EvaluatePharma reports (2022).
[3] Market share estimates based on publicly available market analysis reports (2023).
